Storia in 3 fonti

Nonobstructive Heart Enlargement Responds to Aficamten

Trial results extend range of benefits beyond drug's current indication

Raccontata da

healio.com

medpagetoday.com

medicalxpress.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo2 g fa

Nonobstructive Heart Enlargement Responds to Aficamten

Trial results extend range of benefits beyond drug's current indication

originale

healio.com2 g fa

Aficamten improves health status, exercise capacity in challenging nonobstructive HCM

MUNICH — In patients with symptomatic nonobstructive hypertrophic cardiomyopathy, aficamten led to greater improvements in health status and exercise capacity at 36 weeks compared with placebo, according to data from…

Leggi questa versione → originale

Timeline cronologica

venerdì 28 agosto 2026·healio.com
Aficamten improves health status, exercise capacity in challenging nonobstructive HCM
MUNICH — In patients with symptomatic nonobstructive hypertrophic cardiomyopathy, aficamten led to greater improvements in health status and exercise capacity at 36 weeks compared…
venerdì 28 agosto 2026·medpagetoday.com
Nonobstructive Heart Enlargement Responds to Aficamten
Trial results extend range of benefits beyond drug's current indication

Nonobstructive Heart Enlargement Responds to Aficamten

Confronto fonti

Nonobstructive Heart Enlargement Responds to Aficamten

Aficamten improves health status, exercise capacity in challenging nonobstructive HCM

Timeline cronologica

Aficamten improves health status, exercise capacity in challenging nonobstructive HCM

Nonobstructive Heart Enlargement Responds to Aficamten

Aficamten trial brings positive news for patients living with non-obstructive hypertrophic cardiomyopathy

Aficamten trial brings positive news for patients living with non-obstructive hypertrophic cardiomyopathy